Nature Reviews Cancer 15, 361 (2015)
Building better monoclonal antibody-based therapeutics
George J. Weiner.
For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer therapy, but there is still much room for improvement. Efforts continue to build better cancer therapeutics based on mAbs. Anticancer mAbs function through various mechanisms, including directly targeting the malignant cells, modifying